$20.36
+0.22
(+1.09%)▲
Revenue is up for the last 2 quarters, 25.89M → 28.45M (in $), with an average increase of 9.0% per quarter
Netprofit is up for the last 3 quarters, -35.06M → -6.10M (in $), with an average increase of 146.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 29.8% return, outperforming this stock by 7.7%
In the last 3 years, Stryker Corp. has given 38.5% return, outperforming this stock by 61.3%
1.96%
Downside
Day's Volatility :3.81%
Upside
1.88%
69.01%
Downside
52 Weeks Volatility :73.08%
Upside
13.14%
Period | Quanterix Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 49.82% | 0.9% | -8.3% |
6 Months | 56.62% | -6.8% | -6.5% |
1 Year | 22.14% | 0.4% | -6.1% |
3 Years | -22.76% | 28.3% | 21.8% |
Market Capitalization | 753.4M |
Book Value | $9.55 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.17 |
Wall Street Target Price | 22.75 |
Profit Margin | -81.06% |
Operating Margin TTM | -59.7% |
Return On Assets TTM | -8.36% |
Return On Equity TTM | -21.6% |
Revenue TTM | 104.4M |
Revenue Per Share TTM | 2.81 |
Quarterly Revenue Growth YOY | -3.6999999999999997% |
Gross Profit TTM | 46.8M |
EBITDA | -56.9M |
Diluted Eps TTM | -2.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.33 |
EPS Estimate Next Year | -1.38 |
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Next Quarter | -0.39 |
What analysts predicted
Upside of 11.74%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 22.9M | ↑ 30.08% |
Net Income | -27.0M | ↑ 16.6% |
Net Profit Margin | -118.12% | ↑ 13.66% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 37.6M | ↑ 64.52% |
Net Income | -31.5M | ↑ 16.72% |
Net Profit Margin | -83.8% | ↑ 34.32% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 56.7M | ↑ 50.76% |
Net Income | -40.8M | ↑ 29.36% |
Net Profit Margin | -71.91% | ↑ 11.89% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 86.4M | ↑ 52.25% |
Net Income | -31.5M | ↓ 22.71% |
Net Profit Margin | -36.5% | ↑ 35.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 110.6M | ↑ 27.99% |
Net Income | -57.7M | ↑ 82.96% |
Net Profit Margin | -52.18% | ↓ 15.68% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 105.5M | ↓ 4.55% |
Net Income | -96.7M | ↑ 67.63% |
Net Profit Margin | -91.64% | ↓ 39.46% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 31.3M | ↑ 17.3% |
Net Income | -20.0M | ↑ 27.87% |
Net Profit Margin | -63.99% | ↓ 5.29% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 29.6M | ↓ 5.57% |
Net Income | -18.2M | ↓ 9.35% |
Net Profit Margin | -61.43% | ↑ 2.56% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 23.4M | ↓ 20.73% |
Net Income | -24.9M | ↑ 37.18% |
Net Profit Margin | -106.31% | ↓ 44.88% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 26.6M | ↑ 13.75% |
Net Income | -35.1M | ↑ 40.81% |
Net Profit Margin | -131.59% | ↓ 25.28% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 25.9M | ↓ 2.8% |
Net Income | -18.6M | ↓ 47.01% |
Net Profit Margin | -71.74% | ↑ 59.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.5M | ↑ 9.87% |
Net Income | -6.1M | ↓ 67.15% |
Net Profit Margin | -21.45% | ↑ 50.29% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 91.8M | ↑ 147.27% |
Total Liabilities | 25.9M | ↑ 9.61% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 67.6M | ↓ 26.33% |
Total Liabilities | 26.5M | ↑ 2.44% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 170.0M | ↑ 151.37% |
Total Liabilities | 41.3M | ↑ 55.55% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 271.0M | ↑ 59.48% |
Total Liabilities | 64.9M | ↑ 57.22% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 501.5M | ↑ 85.03% |
Total Liabilities | 60.6M | ↓ 6.69% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 434.2M | ↓ 13.42% |
Total Liabilities | 75.3M | ↑ 24.24% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 501.5M | ↓ 1.82% |
Total Liabilities | 60.6M | ↑ 9.49% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 504.7M | ↑ 0.62% |
Total Liabilities | 78.2M | ↑ 29.18% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 488.6M | ↓ 3.18% |
Total Liabilities | 83.1M | ↑ 6.26% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 446.7M | ↓ 8.58% |
Total Liabilities | 73.9M | ↓ 11.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 434.2M | ↓ 2.8% |
Total Liabilities | 75.3M | ↑ 1.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 427.3M | ↓ 1.59% |
Total Liabilities | 70.0M | ↓ 7.01% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.1M | ↑ 24.6% |
Investing Cash Flow | -1.1M | ↑ 37.05% |
Financing Cash Flow | 73.2M | ↑ 59.53% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.7M | ↑ 29.92% |
Investing Cash Flow | -5.5M | ↑ 381.8% |
Financing Cash Flow | -78.0K | ↓ 100.11% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.2M | ↓ 8.82% |
Investing Cash Flow | -25.4M | ↑ 365.27% |
Financing Cash Flow | 116.2M | ↓ 149070.51% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.4M | ↓ 10.78% |
Investing Cash Flow | -626.0K | ↓ 97.53% |
Financing Cash Flow | 96.2M | ↓ 17.18% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -47.9M | ↑ 105.04% |
Investing Cash Flow | -6.3M | ↑ 912.46% |
Financing Cash Flow | 270.8M | ↑ 181.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -48.3M | ↑ 0.76% |
Investing Cash Flow | -11.2M | ↑ 76.81% |
Financing Cash Flow | 2.3M | ↓ 99.15% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↓ 25.3% |
Investing Cash Flow | -2.2M | ↑ 8.88% |
Financing Cash Flow | -851.0K | ↓ 79.04% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.7M | ↑ 110.79% |
Investing Cash Flow | -874.0K | ↓ 60.16% |
Financing Cash Flow | 979.0K | ↓ 215.04% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↓ 63.4% |
Investing Cash Flow | -5.1M | ↑ 478.95% |
Financing Cash Flow | 211.0K | ↓ 78.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.2M | ↑ 356.45% |
Investing Cash Flow | -3.7M | ↓ 27.33% |
Financing Cash Flow | 1.4M | ↑ 556.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 17.6M | ↓ 148.58% |
Investing Cash Flow | -1.6M | ↓ 56.62% |
Financing Cash Flow | -265.0K | ↓ 119.12% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.5M | ↓ 153.97% |
Investing Cash Flow | -136.0K | ↓ 91.47% |
Financing Cash Flow | 551.0K | ↓ 307.92% |
Sell
Neutral
Buy
Quanterix Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Quanterix Corporation | 10.71% | 56.62% | 22.14% | -22.76% | 8.53% |
![]() Stryker Corporation | -2.22% | 16.98% | 21.98% | 40.5% | 57.79% |
![]() Boston Scientific Corp. | -0.23% | 14.09% | 31.59% | 38.48% | 69.35% |
![]() Edwards Lifesciences Corp. | -2.91% | 15.56% | -11.48% | 20.2% | 79.31% |
![]() Abbott Laboratories | -6.01% | -1.15% | -10.5% | 18.07% | 65.34% |
![]() Medtronic PLC | -6.17% | 6.31% | -12.28% | -13.64% | -4.3% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Quanterix Corporation | NA | NA | NA | -1.33 | -0.22 | -0.08 | 0.0 | 9.55 |
![]() Stryker Corporation | 31.53 | 31.53 | 2.85 | 10.16 | 16.45 | 0.06 | 0.01 | 44.51 |
![]() Boston Scientific Corp. | 85.83 | 85.83 | 2.53 | 1.95 | 0.05 | 0.04 | 0.0 | 12.42 |
![]() Edwards Lifesciences Corp. | 34.98 | 34.98 | 3.07 | 2.55 | 0.25 | 0.13 | 0.0 | 9.87 |
![]() Abbott Laboratories | 24.98 | 24.98 | 18.76 | 4.4 | 16.03 | 0.06 | 0.02 | 21.28 |
![]() Medtronic PLC | 18.03 | 18.03 | 3.04 | 5.28 | 7.81 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Quanterix Corporation | Hold | $753.4M | 8.53% | NA | -81.06% |
![]() Stryker Corporation | Buy | $104.6B | 57.79% | 31.53 | 13.86% |
![]() Boston Scientific Corp. | Buy | $74.0B | 69.35% | 85.83 | 6.92% |
![]() Edwards Lifesciences Corp. | Buy | $51.7B | 79.31% | 34.98 | 27.07% |
![]() Abbott Laboratories | Buy | $178.8B | 65.34% | 24.98 | 13.98% |
![]() Medtronic PLC | Buy | $110.1B | -4.3% | 18.03 | 12.03% |
Camber Capital Management LLC
BlackRock Inc
Vanguard Group Inc
Millennium Management LLC
Frontier Capital Management CO Inc
Granahan Investment Management Inc..
Quanterix Corporation’s price-to-earnings ratio stands at None
Read MoreQuanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Organization | Quanterix Corporation |
Employees | 370 |
CEO | Dr. Masoud Toloue Ph.D. |
Industry | Health Technology |
ProShares Bitcoin Strategy ETF
$15.29
+1.8%
Invesco Dynamic Software ETF
$105.19
+0.54%
ARROWROOT ACQUISITION CORP-A
$10.38
-0.09%
SimilarWeb Ltd
$6.74
+3.37%
Rimini Street Inc
$4.29
+1.66%
SENTI BIOSCIENCES INC
$0.93
+5.87%
WISDOMTREE US EFFICIENT CORE
$36.20
+0.84%
XOMA CORP
$17.97
+5.64%
Madison Square Garden Entertainment Corporation
$40.09
+9.48%